CompletedNot Applicable

Evaluation of the Role of OCT in the Detection of HIV-associated Neurocognitive Disorder

Belgium55 participantsStarted 2015-04

Plain-language summary

The purpose of this study is to determine the sensitivity and specificity of the use of optical coherence tomography to detect HIV-associated neurocognitive disorder compared to MRI and usual cognitive screening tools.

Who can participate

Age range18 Years – 65 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * HIV infection * Antiretroviral treatment * Undetectable plasmatic HIV viral load (viral load\<50 copies/ml) for at least 6 months * Ability to understand and give approved consent Exclusion Criteria: * Any present or past ophthalmologic illness that may impair OCT results * Previous cerebral infection with sequel * Previous cerebrovascular disease with sequel * Severe psychiatric illness * Active alcohol or drug abuse * Active chronic hepatitis C * Inability to perform french cognitive assessment * Inability to perform a MRI * Inability to perform a lumbar puncture

What they're measuring

Number of patients with abnormal OCT (retinal thickness in µm) in patients with abnormal full neurocognitive evaluation

Timeframe: Baseline

Trial details

NCT IDNCT02431091

SponsorCentre Hospitalier Universitaire Saint Pierre

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2022-03

View on ClinicalTrials.gov More AIDS-Related Dementia Complex trials